Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study Target Current Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ Treatment Investigator’s Global Assessment (IGA) Materially Improved from Baseline 4 (Severe) to 0 (Clear) Pruritus (itch) Reduced from 5… Read More..

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) --  Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty… Read More..

MIAMI, Oct. 09, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 100 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become… Read More..